Efficacia della metaciclina nell'acne moderata: Risultati preliminari

Translated title of the contribution: Efficacy of methacycline in moderate acne vulgaris: Preliminary results

D. Innocenzi, C. Rota, V. Pacifico, F. Bruni, F. Lupi, C. Panetta, N. Skroza

Research output: Contribution to journalArticle

Abstract

Aim: To study the efficacy and safety of systemic methacycline in moderate inflammatory acne vulgaris. Patients and Methods: An open-label non comparative study was carried out for 8 weeks at the Department of Dermatology and Plastic Surgery of "La Sapienza" University in Rome. Twenty-five patients (11 women, 14 men), between 15 and 35 years of age (mean age ± 22 years), affected by moderate inflammatory acne vulgaris, were enrolled in this study. Patients were treated with topical adapalene 0,1% gel o cream (in the evening) in association with systemic methacycline (300 mg orally twice daily for 6 weeks of therapy, then 300 mg orally once daily for the last two weeks). Patients were examined at baseline, 4 weeks and 8 weeks (end of study), evaluating both clinical (Global Acne Grading System, GAGS) and quality of life (Acne Quality of Life Questionnaire, AQoL) improvement. Results: 22 patients completed the study and showed significant improvement. Side effects (abnominal pain) were recorded in only 4 patients and 3 of them interrupted the treatment. Conclusion: Systemic methacycline is a safe and effective treatment of moderate inflammatory acne vulgaris with an excellent patient compliance.

Original languageItalian
Pages (from-to)15-18
Number of pages4
JournalDermatologia Clinica
Volume26
Issue number1
Publication statusPublished - Jan 2006

Fingerprint

Methacycline
Acne Vulgaris
Quality of Life
Plastic Surgery
Patient Compliance
Dermatology
Therapeutics
Gels
Safety
Pain

ASJC Scopus subject areas

  • Dermatology

Cite this

Innocenzi, D., Rota, C., Pacifico, V., Bruni, F., Lupi, F., Panetta, C., & Skroza, N. (2006). Efficacia della metaciclina nell'acne moderata: Risultati preliminari. Dermatologia Clinica, 26(1), 15-18.

Efficacia della metaciclina nell'acne moderata : Risultati preliminari. / Innocenzi, D.; Rota, C.; Pacifico, V.; Bruni, F.; Lupi, F.; Panetta, C.; Skroza, N.

In: Dermatologia Clinica, Vol. 26, No. 1, 01.2006, p. 15-18.

Research output: Contribution to journalArticle

Innocenzi, D, Rota, C, Pacifico, V, Bruni, F, Lupi, F, Panetta, C & Skroza, N 2006, 'Efficacia della metaciclina nell'acne moderata: Risultati preliminari', Dermatologia Clinica, vol. 26, no. 1, pp. 15-18.
Innocenzi D, Rota C, Pacifico V, Bruni F, Lupi F, Panetta C et al. Efficacia della metaciclina nell'acne moderata: Risultati preliminari. Dermatologia Clinica. 2006 Jan;26(1):15-18.
Innocenzi, D. ; Rota, C. ; Pacifico, V. ; Bruni, F. ; Lupi, F. ; Panetta, C. ; Skroza, N. / Efficacia della metaciclina nell'acne moderata : Risultati preliminari. In: Dermatologia Clinica. 2006 ; Vol. 26, No. 1. pp. 15-18.
@article{6bde8f9524d24098bd95d94d39a1c3d9,
title = "Efficacia della metaciclina nell'acne moderata: Risultati preliminari",
abstract = "Aim: To study the efficacy and safety of systemic methacycline in moderate inflammatory acne vulgaris. Patients and Methods: An open-label non comparative study was carried out for 8 weeks at the Department of Dermatology and Plastic Surgery of {"}La Sapienza{"} University in Rome. Twenty-five patients (11 women, 14 men), between 15 and 35 years of age (mean age ± 22 years), affected by moderate inflammatory acne vulgaris, were enrolled in this study. Patients were treated with topical adapalene 0,1{\%} gel o cream (in the evening) in association with systemic methacycline (300 mg orally twice daily for 6 weeks of therapy, then 300 mg orally once daily for the last two weeks). Patients were examined at baseline, 4 weeks and 8 weeks (end of study), evaluating both clinical (Global Acne Grading System, GAGS) and quality of life (Acne Quality of Life Questionnaire, AQoL) improvement. Results: 22 patients completed the study and showed significant improvement. Side effects (abnominal pain) were recorded in only 4 patients and 3 of them interrupted the treatment. Conclusion: Systemic methacycline is a safe and effective treatment of moderate inflammatory acne vulgaris with an excellent patient compliance.",
keywords = "Inflammatory acne vulgaris, Methacycline",
author = "D. Innocenzi and C. Rota and V. Pacifico and F. Bruni and F. Lupi and C. Panetta and N. Skroza",
year = "2006",
month = "1",
language = "Italian",
volume = "26",
pages = "15--18",
journal = "Dermatologia Clinica",
issn = "0392-1395",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "1",

}

TY - JOUR

T1 - Efficacia della metaciclina nell'acne moderata

T2 - Risultati preliminari

AU - Innocenzi, D.

AU - Rota, C.

AU - Pacifico, V.

AU - Bruni, F.

AU - Lupi, F.

AU - Panetta, C.

AU - Skroza, N.

PY - 2006/1

Y1 - 2006/1

N2 - Aim: To study the efficacy and safety of systemic methacycline in moderate inflammatory acne vulgaris. Patients and Methods: An open-label non comparative study was carried out for 8 weeks at the Department of Dermatology and Plastic Surgery of "La Sapienza" University in Rome. Twenty-five patients (11 women, 14 men), between 15 and 35 years of age (mean age ± 22 years), affected by moderate inflammatory acne vulgaris, were enrolled in this study. Patients were treated with topical adapalene 0,1% gel o cream (in the evening) in association with systemic methacycline (300 mg orally twice daily for 6 weeks of therapy, then 300 mg orally once daily for the last two weeks). Patients were examined at baseline, 4 weeks and 8 weeks (end of study), evaluating both clinical (Global Acne Grading System, GAGS) and quality of life (Acne Quality of Life Questionnaire, AQoL) improvement. Results: 22 patients completed the study and showed significant improvement. Side effects (abnominal pain) were recorded in only 4 patients and 3 of them interrupted the treatment. Conclusion: Systemic methacycline is a safe and effective treatment of moderate inflammatory acne vulgaris with an excellent patient compliance.

AB - Aim: To study the efficacy and safety of systemic methacycline in moderate inflammatory acne vulgaris. Patients and Methods: An open-label non comparative study was carried out for 8 weeks at the Department of Dermatology and Plastic Surgery of "La Sapienza" University in Rome. Twenty-five patients (11 women, 14 men), between 15 and 35 years of age (mean age ± 22 years), affected by moderate inflammatory acne vulgaris, were enrolled in this study. Patients were treated with topical adapalene 0,1% gel o cream (in the evening) in association with systemic methacycline (300 mg orally twice daily for 6 weeks of therapy, then 300 mg orally once daily for the last two weeks). Patients were examined at baseline, 4 weeks and 8 weeks (end of study), evaluating both clinical (Global Acne Grading System, GAGS) and quality of life (Acne Quality of Life Questionnaire, AQoL) improvement. Results: 22 patients completed the study and showed significant improvement. Side effects (abnominal pain) were recorded in only 4 patients and 3 of them interrupted the treatment. Conclusion: Systemic methacycline is a safe and effective treatment of moderate inflammatory acne vulgaris with an excellent patient compliance.

KW - Inflammatory acne vulgaris

KW - Methacycline

UR - http://www.scopus.com/inward/record.url?scp=33745683726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745683726&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:33745683726

VL - 26

SP - 15

EP - 18

JO - Dermatologia Clinica

JF - Dermatologia Clinica

SN - 0392-1395

IS - 1

ER -